Our Services
Medical Information
Helpful Resources
Published on: 8/18/2026
Fibroblast growth factor 23 (FGF23) results only make sense when read beside phosphate, calcium, PTH, v
Fibroblast Growth Factor 23 (FGF23) is a hormone produced by bone cells that helps regulate phosphate and vitamin D levels in your blood. Measuring serum intact FGF23 can help your endocrinologist identify disorders of phosphate metabolism. This guide explains what FGF23 does, when to test it, how to interpret your serum intact FGF23 reference ranges, and what to discuss with your doctor.
Your endocrinologist may order a serum intact FGF23 test if you have unexplained low or high phosphate levels, bone pain, muscle weakness, or signs of CKD.
“Intact” FGF23 refers to the full, biologically active molecule. Unlike assays that detect fragments, an intact FGF23 assay better reflects what’s happening in your body.
Key points:
Reference ranges can differ slightly among laboratories, but typical values are:
When reviewing your report, look for the lab-specific range labeled “reference interval.” Always discuss any value outside that interval with your endocrinologist.
Your doctor may recommend an FGF23 test if you have:
High serum intact FGF23 suggests that your body is trying to eliminate excess phosphate or compensate for high vitamin D:
Possible causes:
Clinical considerations:
Low FGF23 suggests your kidneys are conserving phosphate or there’s low vitamin D activity:
Possible causes:
Clinical considerations:
Interpreting FGF23 is complex. Here’s how you and your doctor can work together:
Understanding your symptoms helps guide diagnosis. You might consider doing a free, online symptom check, using the doctor approved Ubie Symptom Checker to organize your concerns before your appointment.
While FGF23 testing itself is low-risk, some related symptoms may signal serious issues. Contact a healthcare professional right away if you experience:
Your health is a partnership. Discuss your test results in detail with your endocrinologist or primary care provider to ensure accurate diagnosis and safe management. If you notice any severe or sudden symptoms, seek medical attention immediately.
(References)
* Bonewald LF, Wacker MJ. FGF23 production by osteocytes. Pediatr Nephrol. 2013 Apr;28(4):563-8. doi: 10.1007/s00467-012-2309-3. Epub 2012 Sep 16. PMID: 22983423; PMCID: PMC3582753.
* Smith ER, McMahon LP, Holt SG. Fibroblast growth factor 23. Ann Clin Biochem. 2014 Mar;51(Pt 2):203-27. doi: 10.1177/0004563213510708. Epub 2013 Nov 22. PMID: 24269946.
* Fukumoto S. Anti-fibroblast growth factor 23 antibody therapy. Curr Opin Nephrol Hypertens. 2014 Jul;23(4):346-51. doi: 10.1097/01.mnh.0000447012.98357.da. PMID: 24848934.
* Kuczera P, Adamczak M, Wiecek A. Fibroblast Growth Factor-23-A Potential Uremic Toxin. Toxins (Basel). 2016 Dec 8;8(12). doi: 10.3390/toxins8120369. Epub 2016 Dec 8. PMID: 27941640; PMCID: PMC5198563.
* Fauconnier C, Roy T, Gillerot G, Roy C, Pouleur AC, Gruson D. FGF23: Clinical usefulness and analytical evolution. Clin Biochem. 2019 Apr;66:1-12. doi: 10.1016/j.clinbiochem.2019.03.002. Epub 2019 Mar 7. PMID: 30853324.
* Simic P, Babitt JL, Rhee EP. Glycerol-3-phosphate and fibroblast growth factor 23 regulation. Curr Opin Nephrol Hypertens. 2021 Jul 1;30(4):397-403. doi: 10.1097/MNH.0000000000000715. PMID: 33901058; PMCID: PMC8312345.
* Ivey-Miranda JB, Stewart B, Cox ZL, McCallum W, Maulion C, Gleason O, Meegan G, Amatruda JG, Moreno-Villagomez J, Mahoney D, Turner JM, Wilson FP, Estrella MM, Shlipak MG, Rao VS, Testani JM. FGF-23 (Fibroblast Growth Factor-23) and Cardiorenal Interactions. Circ Heart Fail. 2021 Nov;14(11):e008385. doi: 10.1161/CIRCHEARTFAILURE.121.008385. Epub 2021 Oct 25. PMID: 34689571; PMCID: PMC8782627.
* Simic P, Babitt JL. Regulation of FGF23: Beyond Bone. Curr Osteoporos Rep. 2021 Dec;19(6):563-573. doi: 10.1007/s11914-021-00703-w. Epub 2021 Nov 10. PMID: 34757587; PMCID: PMC8958553.
* Ito N, Hidaka N, Kato H. Acquired Forms of Fibroblast Growth Factor 23-Related Hypophosphatemic Osteomalacia. Endocrinol Metab (Seoul). 2024 Apr;39(2):255-261. doi: 10.3803/EnM.2023.1908. Epub 2024 Mar 11. PMID: 38467164; PMCID: PMC11066443.
* Takashi Y, Kawanami D, Fukumoto S. Recent advances in fibroblast growth factor 23-related hypophosphatemic disorders. Curr Opin Endocrinol Diabetes Obes. 2024 Aug 1;31(4):170-175. doi: 10.1097/MED.0000000000000866. Epub 2024 Apr 30. PMID: 38687287.
We would love to help them too.
For First Time Users
We provide a database of explanations from real doctors on a range of medical topics. Get started by exploring our library of questions and topics you want to learn more about.
Was this page helpful?
Purpose and positioning of servicesUbie Doctor's Note is a service for informational purposes. The provision of information by physicians, medical professionals, etc. is not a medical treatment. If medical treatment is required, please consult your doctor or medical institution. We strive to provide reliable and accurate information, but we do not guarantee the completeness of the content. If you find any errors in the information, please contact us.